Cygnus Bio key facts
- Operator of a biotechnology firm specializing in the research and development and industrialization of gene sequencing platforms.
- It has raised $71.2M; the latest was Later Stage VC ($14.0M) in Oct 2025.
- Notable investors include Source Code Capital, Shun Xi Fund, Lapam Capital, Guolian Investment, Founder Hesheng Investment — 21 tracked in total.
- Status: Privately Held (backing).
Who backs Cygnus Bio
21+- ·The complete investor list: 21 names
- ·Watch Cygnus Bio: the Monday email on marks, rounds and moves
Cygnus Bio funding rounds
No funding rounds for Cygnus Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Cygnus Bio investors
21 investors are on record for Cygnus Bio, including Source Code Capital, Shun Xi Fund, Lapam Capital and Guolian Investment.
About Cygnus Bio
Operator of a biotechnology firm specializing in the research and development and industrialization of gene sequencing platforms. The company incorporates the use of gene sequencing technology to provide accurate, simple and fast overall biotech solutions, providing genetic engineers and gene therapy specialists with accurate data inputs and readings that help them conduct research experiments and draw conclusions on the same in an effective, efficient and error-free manner.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2015
- Employees
- 99
- Website
- cygnusbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Cygnus Bio doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.